Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

90.37USD
17 Aug 2018
Change (% chg)

$0.22 (+0.24%)
Prev Close
$90.15
Open
$89.97
Day's High
$90.97
Day's Low
$89.26
Volume
1,432,810
Avg. Vol
2,177,144
52-wk High
$147.13
52-wk Low
$74.14

Latest Key Developments (Source: Significant Developments)

Celgene Q2 Earnings Per Share $1.43
Thursday, 26 Jul 2018 07:30am EDT 

July 26 (Reuters) - Celgene Corp ::CELGENE REPORTS SECOND QUARTER 2018 OPERATING AND FINANCIAL RESULTS.Q2 REVENUE $3.814 BILLION VERSUS I/B/E/S VIEW $3.7 BILLION.Q2 EARNINGS PER SHARE $1.43.Q2 EARNINGS PER SHARE VIEW $2.11 -- THOMSON REUTERS I/B/E/S.RAISING FULL-YEAR TOTAL REVENUE GUIDANCE TO ABOUT $15 BILLION AND REVLIMID NET SALES TO ABOUT $9.7 BILLION.QTRLY ADJUSTED EARNINGS PER SHARE $2.16.REVLIMID SALES FOR Q2 INCREASED 21 PERCENT TO $2,453 MILLION.OTEZLA SALES FOR Q2 WERE $375 MILLION, A 5 PERCENT INCREASE YEAR-OVER-YEAR.SEES 2018 EARNINGS PER SHARE $5.95-$6.25.SEES 2018 ADJUSTED DILUTED EPS IN RANGE OF $8.70- $8.75.FY2018 EARNINGS PER SHARE VIEW $8.52, REVENUE VIEW $14.93 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Celgene Meets Main Goal In Study Of Revlimid In Combination With Rituximab
Monday, 23 Jul 2018 04:30pm EDT 

July 23 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES PHASE III ‘AUGMENT’ STUDY OF REVLIMID® IN COMBINATION WITH RITUXIMAB (R2) FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY INDOLENT LYMPHOMA MET PRIMARY ENDPOINT.CELGENE - FINAL ANALYSIS SHOWED HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL FOR R2 COMPARED WITH RITUXIMAB PLUS PLACEBO.CELGENE CORP - DATA FROM AUGMENT WILL BE SUBMITTED TO A FUTURE MEDICAL MEETING & CO PLANS TO PREPARE GLOBAL REGULATORY SUBMISSIONS IN Q1 OF 2019.CELGENE CORP - A FAVORABLE TREND WAS OBSERVED FOR OVERALL SURVIVAL (OS) DURING THE ANALYSIS.CELGENE CORP - FOLLOW-UP WILL CONTINUE FOR THE MATURE OS RESULTS.CELGENE - REVLIMID CAN LEAD TO EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, AND VENOUS AND ARTERIAL THROMBOEMBOLISM.  Full Article

Prothena Announces Global Neuroscience Research & Development Collaboration With Celgene
Tuesday, 20 Mar 2018 04:05pm EDT 

March 20 (Reuters) - Prothena Corporation Plc ::PROTHENA ANNOUNCES GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE FOR NOVEL THERAPIES FOR PATIENTS WITH NEURODEGENERATIVE DISEASES.PROTHENA CORPORATION - PROTHENA TO RECEIVE A $100 MILLION UPFRONT PAYMENT AND A $50 MILLION EQUITY INVESTMENT BY CELGENE.PROTHENA CORPORATION- COLLABORATION INCLUDES POTENTIAL LICENSE PAYMENTS, MILESTONES, PLUS ADDITIONAL ROYALTIES ON SALES FROM LICENSED PROGRAMS FOR CO.PROTHENA CORPORATION PLC - CELGENE WILL SUBSCRIBE TO ABOUT 1.2 MILLION OF PROTHENA'S ORDINARY SHARES AT $42.57 PER SHARE.  Full Article

Beigene Announces Approval Of Revlimid In China
Tuesday, 27 Feb 2018 06:00pm EST 

Feb 27 (Reuters) - Beigene Ltd ::BEIGENE ANNOUNCES APPROVAL OF REVLIMID® FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA.BEIGENE LTD - ‍REVLIMID HAS BEEN APPROVED BY CHINA FOOD AND DRUG ADMINISTRATION FOR TREATMENT OF MULTIPLE MYELOMA​.  Full Article

FDA rejects filing for Celgene MS drug
Tuesday, 27 Feb 2018 04:30pm EST 

Feb 27 (Reuters) - Celgene Corp ::CELGENE PROVIDES REGULATORY UPDATE ON OZANIMOD FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS.CELGENE CORP - ‍FDA DETERMINED NONCLINICAL AND CLINICAL PHARMACOLOGY SECTIONS IN NDA WERE INSUFFICIENT TO PERMIT A COMPLETE REVIEW​.CELGENE - CO INTENDS TO SEEK IMMEDIATE GUIDANCE, INCLUDING REQUESTING A TYPE A MEETING WITH FDA.CELGENE - GOT REFUSAL TO FILE LETTER FROM FDA ABOUT CO'S NDA FOR OZANIMOD IN DEVELOPMENT FOR TREATING PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS.CELGENE - ‍SEEKING GUIDANCE WHICH INCLUDES REQUESTING MEETING WITH FDA, TO ASCERTAIN WHAT ADDITIONAL DATA WILL BE REQUIRED TO RESUBMIT NDA​.  Full Article

Celgene Receives Antitrust Clearance For Juno Acquisition
Wednesday, 21 Feb 2018 07:30am EST 

Feb 21 (Reuters) - Celgene Corp ::CELGENE RECEIVES ANTITRUST CLEARANCE FOR JUNO ACQUISITION.CELGENE CORP - ‍CELGENE EXPECTS JUNO TRANSACTION TO CLOSE IN Q1 OF 2018​.  Full Article

Celgene Says Otezla Phase II Data Showed Clinically Meaningful Improvements In Active Ulcerative Colitis Patients
Thursday, 15 Feb 2018 09:30am EST 

Feb 15 (Reuters) - Celgene Corp ::OTEZLA® (APREMILAST) PHASE II DATA SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS.CELGENE CORP - ‍PHASE III PROGRAM WITH OTEZLA (APREMILAST) IN ULCERATIVE COLITIS EXPECTED TO BEGIN IN 2018​.CELGENE CORP - ‍PRIMARY ENDPOINT OF STUDY WAS TOTAL MAYO SCORE CLINICAL REMISSION AT WEEK 12 FOR 40 MG BID ARM​.  Full Article

Celgene Announces Additional $5 Billion Share Repurchase Authorization
Wednesday, 14 Feb 2018 07:30am EST 

Feb 14 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES ADDITIONAL $5 BILLION SHARE REPURCHASE AUTHORIZATION.CELGENE ANNOUNCES ADDITIONAL $5 BILLION SHARE REPURCHASE AUTHORIZATION.CELGENE CORP - ‍OPEN-ENDED PROGRAM IS EFFECTIVE IMMEDIATELY​.  Full Article

Celgene Prices $4.5 Billion Of Senior Unsecured Notes
Friday, 9 Feb 2018 07:30am EST 

Feb 9 (Reuters) - Celgene Corp ::CELGENE PRICES $4.5 BILLION OF SENIOR UNSECURED NOTES.CELGENE CORP - ANNOUNCED PRICING OF FOUR SERIES OF SENIOR UNSECURED NOTES.CELGENE CORP - NOTES OF $500 MILLION WILL MATURE IN 2021 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 2.875 PERCENT.CELGENE CORP - NOTES OF $1.0 BILLION WILL MATURE IN 2023 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 3.25 PERCENT.CELGENE CORP - NOTES OF $1.5 BILLION WILL MATURE IN 2028 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 3.90 PERCENT.CELGENE CORP - NOTES OF $1.5 BILLION WILL MATURE IN 2048 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 4.55 PERCENT.CELGENE CORP - 2.875 PERCENT NOTES DUE 2021, 3.25 PERCENT NOTES DUE 2023, 3.90 PERCENT NOTES DUE IN 2028 , 4.55 PERCENT NOTES DUE IN 2048.  Full Article

Celgene Announces Offering Of Senior Unsecured Notes
Thursday, 8 Feb 2018 08:55am EST 

Feb 8 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES OFFERING OF SENIOR UNSECURED NOTES.CELGENE CORP - EXPECTS TO USE NET PROCEEDS FROM OFFERING TO FINANCE A PORTION OF ACQUISITION OF JUNO THERAPEUTICS.  Full Article

Celgene profit tops expectations, will limit future price hikes

Celgene Corp on Thursday posted better-than-expected second quarter profit, powered by a 21 percent jump in sales of its blockbuster cancer drug Revlimid, and the U.S. biotech promised to limit future price increases on its medicines. The company joined several rivals in bowing to pressure from the administration of U.S. President Donald Trump to rein in rising costs of prescription drugs to U.S. patients.